Overview

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
1999-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Liraglutide